TIM-3は,炎症体活性化を調節することによって,抗腫瘍免疫を抑制する
Karen O Dixon1,2,3, Marcin Tabaka3, Markus A Schramm1,2,4
1Evergrande Center for Immunologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Nature
|June 10, 2021
まとめ
T細胞ではなく,デンドリット細胞のT細胞免疫 globulinとムシン含有分子3 (TIM- 3) をブロックすると,抗腫瘍免疫が強化されます. dendritic 細胞の TIM - 3 の喪失は,この免疫反応に不可欠な NLRP3 炎症体を活性化します.
科学分野:
- 免疫学
- 癌 生物学
- 細胞免疫学
背景:
- T細胞免疫グロブリンおよびムシン含有分子3 (TIM-3) は,がん治療における免疫チェックポイント分子である.
- CD8+ T細胞のTIM-3発現は機能不全を意味するが,他の免疫細胞のTIM-3発現は治療戦略を複雑にする.
研究 の 目的:
- 腫瘍の微小環境内の異なる免疫細胞におけるTIM-3の特定の役割を調査する.
- TIM-3ブロックが抗腫瘍免疫を促進するメカニズムを解明する.
主な方法:
- TIM-3の条件付きノックアウトモデル
- 単細胞RNAのシーケンス
- 免疫細胞集団とサイトカイン生成の分析
主要な成果:
- T細胞ではなく, dendritic cells (デンドリット細胞) に特化したTIM-3の喪失は,抗腫瘍免疫を著しく強化した.
- DCにおけるTIM-3の消去は,CD8+エフェクタと幹細胞のようなT細胞を促進する制御プログラムを阻害した.
- 活性酸素種が蓄積され,NLRP3炎症体が活性化され,その後IL- 1βとIL- 18が生成された.
結論:
- TIM-3は dendritic 細胞機能を調節する上で重要な役割を果たします.
- TIM-3ブロックは,DCにおける炎症体活性化によって,抗腫瘍免疫を促進する.
- TIM-3を dendritic 細胞に標的にすることは,がんの免疫療法における有望な治療戦略です.
さらに関連する動画
関連する概念動画
The Tumor Microenvironment
7.1K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.1K
Abnormal Proliferation
4.8K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Tumor Immunotherapy
791
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
791
T Cell Types and Functions
1.6K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.6K
mTOR Signaling and Cancer Progression
4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.0K
TGF - β Signaling Pathway
8.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.2K


